secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027712
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools reports Q4 pro forma revenue $46.7M, down 9% YoY; 2025 guidance $165-175M
--------------------------------------------------------------------------------

- Q4 pro forma revenue $46.7M (down 9% YoY); full year $175.1M (down 9% YoY).
- Q4 net loss $34.1M improved from $55.3M loss; adjusted EBITDA loss $18.4M (34% improvement).
- Achieved $90M in operational cost synergies, exceeding original target by $10M; cash $295M, no debt.
- 2025 revenue guidance $165M-$175M, citing anticipated NIH funding pressure and no tariff impact.
- Full year consumables revenue up 18% YoY; instruments down 27%; services down 17%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025027712/0000950170-25-027712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025027712/lab-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer